Author:
Ishiguro Naoki,Oyabu Masanobu,Sato Toshihiro,Maeda Tomoji,Minami Hironobu,Tamai Ikumi
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference39 articles.
1. S. H. Landis, T. Murray, S. Bolden, and P. A. Wingo. Cancer statistics, 1999. CA Cancer J. Clin. 49:8–31, 1 (1999).
2. A. Inoue, Y. Saijo, M. Maemondo, K. Gomi, Y. Tokue, Y. Kimura, M. Ebina, T. Kikuchi, T. Moriya, and T. Nukiwa. Severe acute interstitial pneumonia and gefitinib. Lancet 361:137–139 (2003).
3. I. Okamoto, K. Fujii, M. Matsumoto, Y. Terasaki, N. Kihara, H. Kohrogi, and M. Suga. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer 40:339–42 (2003).
4. N. Thatcher, A. Chang, P. Parikh, J. Rodrigues Pereira, T. Ciuleanu, J. von Pawel, S. Thongprasert, E. H. Tan, K. Pemberton, V. Archer, and K. Carroll. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527–1537 (2005).
5. K. Aoe, A. Hiraki, T. Murakami, T. Maeda, Y. Umemori, H. Katayama, R. Eda, and H. Takeyama. Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy. Anticancer Res. 25:415–418 (2005).
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献